Author:
Sacramento Caroline Q.,de Melo Gabrielle R.,Rocha Natasha,Bôas Hoelz Lucas Villas,Mesquita Milene,de Freitas Caroline S.,Fintelman Rodrigues Natalia,Marttorelli Andressa,Ferreiral André C.,Barbosa-Lima Giselle,Bastos Mônica M.,de Mello Volotão Eduardo,Tschoeke Diogo A.,Leomil Luciana,Bozza Fernando A.,Bozza Patrícia T.,Boechat Nubia,Thompson Fabiano L.,de Filippis Ana M. B.,Brüning Karin,Souza Thiago Moreno L.
Abstract
SummaryZika virus (ZIKV) is a member of Flaviviridae family, as other agents of clinical significance, such as dengue (DENV) and hepatitis C (HCV) viruses. ZIKV spread from Africa to Pacific and South American territories, emerging as an etiological pathogen of neurological disorders, during fetal development and in adulthood. Therefore, antiviral drugs able to inhibit ZIKV replication are necessary. Broad spectrum antivirals, such as interferon, ribavirin and favipiravir, are harmful for pregnant animal models and women. The clinically approved uridine nucleotide analog anti-HCV drug, sofosbuvir, has not been affiliated to teratogenicity. Sofosbuvir target the most conserved protein over the members of the Flaviviridae family, the viral RNA polymerase. We thus studied ZIKV susceptibility to sofosbovir. We initially characterized a Brazilian ZIKV strain for use in experimental assays. Sofosbuvir inhibits the Brazilian ZIKV replication in a dose-dependent manner, both in BHK-21 cells and SH-Sy5y, by targeting ZIKV RNA polymerase activity, with the involvement of conserved amino acid residues over the members of Flaviviridae family. The identification of clinically approved antiviral drugs endowed with anti-ZIKV could reduce the time frame in pre-clinical development. Altogether, our data indicates that sofosbuvir chemical structure is endowed with anti-ZIKV activity.
Publisher
Cold Spring Harbor Laboratory
Reference47 articles.
1. Zika Virus;Clin Microbiol Rev.,2016
2. Potential sexual transmission of Zika virus;Emerg Infect Dis.,2015
3. Zika virus. I. Isolations and serological specificity;Trans RSoc Trop Med Hyg.,1952
4. Mitochondrial disease therapy from thin air?
5. Use of ChAd3-EBO-Z Ebola virus vaccine in Malian and US adults, and boosting of Malian adults with MVA-BN-Filo: a phase 1, single-blind, randomised trial, a phase 1b, open-label and double-blind, dose-escalation trial, and a nested, randomised, double-blind, placebo-controlled trial
Cited by
10 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献